<You are mixing bio-pseudo-science and business operations, a deadly mistake in this business, and doubly deadly in science.>
Drug companies must mix science and business. The marketer, physician, biologist, chemist, and accountant all bring something crucial to the table.
In re: Glaxo, it has outgained the S&P considerably, and has outperformed the Philly Pharm index ($DRG) over the time frame mentioned by Miljenko. I don't pretend this is a triumph of pure science: GLX's AIDS franchise was assembled from buying Wellcome (AZT), licensing 3TC from Biochem, and collaborating with Vertex (141W). Their new nuke NRTI, 1592, was the exception. Sure, success may have come from monkey-lawyers on typewriters. Nevertheless, management saw the empty pipeline problem and took steps to fill it up. Prosaic as that may be, investors have benefitted.
Other managements are calling on ArQule to help fill their pipes fast, and investors are benefitting therefrom. |
